Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD
Sponsor: Transcend Therapeutics
Summary
This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter an 8-week Follow-up Period.
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2026-09
Completion Date
2028-02
Last Updated
2026-09-23
Healthy Volunteers
No
Conditions
Interventions
TSND-201
TSND-201 capsules, given orally, once a week for four consecutive weeks
Placebo
Placebo capsules, given orally, once a week for four consecutive weeks
Locations (2)
Mountain View Clinical Research
Denver, Colorado, United States
Bradenton Research Center
Bradenton, Florida, United States